Advanced Immunization Technologies (ADITEC) is a European Union (EU)–supported consortium that is funded by the Seventh Framework Programme to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.

**Research Areas**
- Tool Development
- Basic Research

**At a Glance**
- Status: Active Consortium
- Year Launched: 2011
- Initiating Organization: European Commission Seventh Framework Programme (FP7)
- Initiator Type: Government
- Location: International

**Abstract**

Advanced Immunization Technologies (ADITEC) is a European Union (EU)–supported consortium that is funded by the Seventh Framework Programme to accelerate the development of novel and powerful immunization technologies for the next generation of human vaccines.

**Mission**

**Consortium History**

The science behind vaccine development has not been coordinated and is the focus for the
consortium, which brings together European research groups from public institutions and biotechnology companies, together with top U.S. groups on systems biology and adjuvants.

Structure & Governance

impact report

Homepage http://www.aditecproject.eu/

Points of Contact

Sponsors & Partners

ALTA s.r.l.u
ArenaVax
Bioneedle Group
Crossbeta Biosciences
deCODE Genetics
Duotol AB
Emory University
Erasmus Medical Center
Fondazione Humanitas per la Ricerca
Fondazione per l'Istituto di Ricerca in Biomedicina
French Atomic Energy
Imperial College London
Infectious Disease Research Institute
Institut de Biologie et Chimie des Protéines
Institute for Biomedical Aging Research
Institute Pasteur
Intercell
Istituto Superiore di Sanità
Kings College London
Leiden University
Max Planck Institute for Infection Biology
Medicine in need
Microbiotec srl
National Institute for Biological Standards and Control
Novartis Vaccines and Diagnostics
Novartis Vaccines Institute for Global Health
Okairos
Pevion Biotech
Sclavo Vaccines Association
Seattle Biomedical Research Institute
Sigmoid Pharma
St George University of London
Statens Serum Institut
Tuberculosis Vaccine Initiative
University of Geneva
University of Goteborg
University of Oxford
University of Siena
Utrecht University
Vaccibody
World Health Organization
Xbrane Bioscience AB

Updated: 04/20/2016